Drug Trial Radar · NCT05380492
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
Last checked: Nov 19, 2026Latest source record: Apr 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
45
Planned (sponsor's estimate)
Start
Nov 17, 2022
Primary completion
Nov 2025
Study completion Nov 2025
Sponsor
- Lead sponsor
- Perceive Biotherapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This safety study comprises a dose escalation study of VOY-101, followed by a cohort of subjects randomized to the maximum tolerated dose arm, a lower dose arm, and control arm.
Conditions
- Age-related Macular Degeneration
- Geographic Atrophy
Interventions
VOY-101Biological
Intravitreal injection of VOY-101
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety EndpointsTime frame: Through 24 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Ophthalmic Consultants of Boston
Boston, Massachusetts
Retina Consultants of Texas
Bellaire, Texas
University of Utah
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.